BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis.
Level 4 - case-series / case-control
Retrospective analysis of a passive surveillance reporting database (VAERS) with risk-benefit modeling
PubMed 35156705 · doi:10.1111/eci.13759
What was done
The authors used the Vaccine Adverse Event Reporting System (VAERS) to identify cases of BNT162b2 (Pfizer-BioNTech) associated myo/pericarditis in adolescents aged 12–17 using CDC criteria. They calculated crude post-vaccination incidence after dose 1 and dose 2 for ages 12–15 and 16–17. They then conducted risk-benefit analyses comparing post-vaccination myo/pericarditis hospitalizations against COVID-19 hospitalizations prevented, stratified by age, sex, comorbidities, history of prior infection, and viral variant (Delta vs. Omicron).
What was found
A total of 253 myo/pericarditis cases were identified (129 after dose 1, 124 after dose 2), with 86.9% requiring hospitalization. In males, crude incidence per million after dose 2 was 162.2 in ages 12–15 and 93.0 in ages 16–17. In Delta-era risk-benefit modeling, two-dose vaccination was uniformly favorable only in nonimmune adolescent girls with a comorbidity. For boys with prior SARS-CoV-2 infection and no comorbidities, even a single dose carried higher modeled risk than benefit. Under Omicron assumptions, one dose was estimated to offer protection in nonimmune children, but a second dose did not confer additional net population benefit.
Why it matters
These findings suggest that adolescent mRNA vaccination strategies should be individualized by sex, baseline health status, prior infection, and prevailing variant risk rather than applied as a uniform multi-dose mandate.
Limits
The study relies on VAERS, a passive reporting system subject to reporting biases, underreporting, and unverified causality. The analysis evaluates hospitalizations as the primary trade-off metric and does not capture long-term sequelae, outpatient illness, or viral transmission dynamics, while baseline COVID-19 risk assumptions fluctuate over time.
Cited by
- supports A preprint study analyzing VAERS data claimed that the incidence of post-vaccine myocarditis was higher than the rate of COVID-19 hospitalizations in pediatric patients.